Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197180
Title: | Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients |
Author: | Sans de San Nicolàs, Lídia Figueras Nart, Ignasi García Jiménez, Irene Bonfill Ortí, Montserrat Guilabert, Antonio Curto Barredo, Laia Bertolín Colilla, Marta Ferran, Marta Serra Baldrich, Esther Pujol, Ramon M. Santamaria Babí, Luis F. |
Keywords: | Dermatitis atòpica Al·lèrgens Citocines Cèl·lules T Atopic dermatitis Allergens Cytokines T cells |
Issue Date: | 13-Mar-2023 |
Publisher: | Frontiers Media SA |
Abstract: | Background:The role of allergen sensitization in IL-31 production by T cells and specifically in the clinical context of atopic dermatitis (AD) has not been characterized. MethodsThe response to house dust mite (HDM) in purified memory T cells cocultured with epidermal cells from AD patients (n=58) and control subjects (n=11) was evaluated. AD-associated cytokines from culture supernatants, plasma proteins and mRNA expression from cutaneous lesions were assessed and related with the clinical features of the patients. ResultsHDM-induced IL-31 production by memory T cells defined two subsets of AD patients according to the presence or absence of IL-31 response. Patients in the IL-31 producing group showed a more inflammatory profile, and increased HDM-specific (sp) and total IgE levels compared to the IL-31 non-producing group. A correlation between IL-31 production and patient's pruritus intensity, plasma CCL27 and periostin was detected. When the same patients were analyzed based on sp IgE and total IgE levels, an increased IL-31 in vitro response, as well as type 2 markers in plasma and cutaneous lesions, was found in patients with sp IgE levels > 100 kUA/L and total IgE levels > 1000 kU/L. The IL-31 response by memory T cells was restricted to the cutaneous lymphocyte-associated antigen (CLA)(+) T-cell subset. ConclusionIgE sensitization to HDM allows stratifying IL-31 production by memory T cells in AD patients and relating it to particular clinical phenotypes of the disease. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1124018 |
It is part of: | Frontiers in Immunology, 2023, vol. 14, num. 1124018 |
URI: | http://hdl.handle.net/2445/197180 |
Related resource: | https://doi.org/10.3389/fimmu.2023.1124018 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-1124018.pdf | 2.92 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License